S&P 500   4,374.90 (-1.54%)
DOW   34,454.17 (-1.19%)
QQQ   361.93 (-2.27%)
AAPL   142.72 (-1.82%)
MSFT   286.38 (-2.65%)
FB   343.17 (-2.94%)
GOOGL   2,731.75 (-3.18%)
TSLA   775.64 (-1.99%)
AMZN   3,324.00 (-2.40%)
NVDA   209.27 (-3.38%)
BABA   152.61 (+1.62%)
NIO   35.18 (-4.32%)
CGC   14.28 (-2.92%)
GE   106.10 (+0.71%)
MU   74.09 (-1.45%)
AMD   102.71 (-5.04%)
T   27.26 (-0.51%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.65 (-1.46%)
PFE   43.05 (-1.19%)
BA   219.57 (-2.05%)
AMC   37.65 (-4.20%)
S&P 500   4,374.90 (-1.54%)
DOW   34,454.17 (-1.19%)
QQQ   361.93 (-2.27%)
AAPL   142.72 (-1.82%)
MSFT   286.38 (-2.65%)
FB   343.17 (-2.94%)
GOOGL   2,731.75 (-3.18%)
TSLA   775.64 (-1.99%)
AMZN   3,324.00 (-2.40%)
NVDA   209.27 (-3.38%)
BABA   152.61 (+1.62%)
NIO   35.18 (-4.32%)
CGC   14.28 (-2.92%)
GE   106.10 (+0.71%)
MU   74.09 (-1.45%)
AMD   102.71 (-5.04%)
T   27.26 (-0.51%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.65 (-1.46%)
PFE   43.05 (-1.19%)
BA   219.57 (-2.05%)
AMC   37.65 (-4.20%)
S&P 500   4,374.90 (-1.54%)
DOW   34,454.17 (-1.19%)
QQQ   361.93 (-2.27%)
AAPL   142.72 (-1.82%)
MSFT   286.38 (-2.65%)
FB   343.17 (-2.94%)
GOOGL   2,731.75 (-3.18%)
TSLA   775.64 (-1.99%)
AMZN   3,324.00 (-2.40%)
NVDA   209.27 (-3.38%)
BABA   152.61 (+1.62%)
NIO   35.18 (-4.32%)
CGC   14.28 (-2.92%)
GE   106.10 (+0.71%)
MU   74.09 (-1.45%)
AMD   102.71 (-5.04%)
T   27.26 (-0.51%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.65 (-1.46%)
PFE   43.05 (-1.19%)
BA   219.57 (-2.05%)
AMC   37.65 (-4.20%)
S&P 500   4,374.90 (-1.54%)
DOW   34,454.17 (-1.19%)
QQQ   361.93 (-2.27%)
AAPL   142.72 (-1.82%)
MSFT   286.38 (-2.65%)
FB   343.17 (-2.94%)
GOOGL   2,731.75 (-3.18%)
TSLA   775.64 (-1.99%)
AMZN   3,324.00 (-2.40%)
NVDA   209.27 (-3.38%)
BABA   152.61 (+1.62%)
NIO   35.18 (-4.32%)
CGC   14.28 (-2.92%)
GE   106.10 (+0.71%)
MU   74.09 (-1.45%)
AMD   102.71 (-5.04%)
T   27.26 (-0.51%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.65 (-1.46%)
PFE   43.05 (-1.19%)
BA   219.57 (-2.05%)
AMC   37.65 (-4.20%)
NASDAQ:ERYP

ERYTECH Pharma Stock Forecast, Price & News

$6.01
+0.13 (+2.21 %)
(As of 09/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.80
$6.04
50-Day Range
$4.11
$6.47
52-Week Range
$4.10
$13.00
Volume15,576 shs
Average Volume399,396 shs
Market Capitalization$166.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
30 days | 90 days | 365 days | Advanced Chart
Receive ERYP News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.


ERYTECH Pharma logo

About ERYTECH Pharma

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERYP
Employees
206
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.25 million
Book Value
$1.51 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$166.65 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.77 out of 5 stars

Medical Sector

1281st out of 1,353 stocks

Biological Products, Except Diagnostic Industry

186th out of 195 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












ERYTECH Pharma (NASDAQ:ERYP) Frequently Asked Questions

Is ERYTECH Pharma a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ERYTECH Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ERYTECH Pharma stock.
View analyst ratings for ERYTECH Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than ERYTECH Pharma?

Wall Street analysts have given ERYTECH Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ERYTECH Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ERYTECH Pharma?

ERYTECH Pharma saw a drop in short interest in August. As of August 31st, there was short interest totaling 34,500 shares, a drop of 70.5% from the August 15th total of 116,900 shares. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.1% of the shares of the company are sold short.
View ERYTECH Pharma's Short Interest
.

How has ERYTECH Pharma's stock price been impacted by Coronavirus (COVID-19)?

ERYTECH Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ERYP stock has increased by 14.7% and is now trading at $6.01.
View which stocks have been most impacted by COVID-19
.

Who are ERYTECH Pharma's key executives?

ERYTECH Pharma's management team includes the following people:
  • Gil Beyen, Chief Executive Officer & Director
  • Eric Soyer, Chief Operating & Financial Officer
  • Stewart Craig, Chief Technical Officer
  • Iman El-Hariry, Chief Medical Officer
  • Jérôme Bailly, Chief Quality Officer & Deputy General Manager

What other stocks do shareholders of ERYTECH Pharma own?

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

Who are ERYTECH Pharma's major shareholders?

ERYTECH Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (4.98%).

Which major investors are buying ERYTECH Pharma stock?

ERYP stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL.

How do I buy shares of ERYTECH Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $6.01.

How much money does ERYTECH Pharma make?

ERYTECH Pharma has a market capitalization of $166.65 million and generates $4.25 million in revenue each year. The company earns $-83,730,000.00 in net income (profit) each year or ($4.55) on an earnings per share basis.

How many employees does ERYTECH Pharma have?

ERYTECH Pharma employs 206 workers across the globe.

What is ERYTECH Pharma's official website?

The official website for ERYTECH Pharma is www.erytech.com.

Where are ERYTECH Pharma's headquarters?

ERYTECH Pharma is headquartered at 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at (347) 874-4438 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.